Table 2.
Baseline values and changes in bone remodeling marker values in vildagliptin and gliclazide MR treatment groups
| Variables | Vildagliptin (N = 21) | Gliclazide MR (N = 21) | p value (among groups) |
|---|---|---|---|
| OC (ng/mL) | |||
| Baseline | 12.5 ± 4.2 | 10.2 ± 3.5 | 0.063 |
| Change from baseline to month 6 | 1.0 ± 3.5 | 0.5 ± 2.9 | 0.622 |
| p value* | 0.204 | 0.438 | |
| Change from baseline to month 12 | −0.1 ± 2.9 | 0.6 ± 3.8 | 0.519 |
| p value* | 0.930 | 0.468 | |
| PINP (ng/mL) | |||
| Baseline | 38.1 ± 11.8 | 36.3 ± 14.7 | 0.660 |
| Change from baseline to month 6 | 2.4 ± 14.9 | −0.3 ± 8.3 | 0.475 |
| p value* | 0.462 | 0.887 | |
| CTX (ng/mL) | |||
| Baseline | 0.288 ± 0.139 | 0.197 ± 0.062 | 0.013 |
| Change from baseline to month 6 | 0.010 ± 0.071 | 0.029 ± 0.052 | 0.355 |
| p value* | 0.523 | 0.023 | |
| Change from baseline to month 12 | 0.001 ± 0.153 | 0.008 ± 0.060 | 0.858 |
| p value* | 0.563 | 0.972 | |
| U-NTX (nmol/BCE/mmol creatinine) | |||
| Baseline | 41.1 ± 16.5 | 35.6 ± 14.4 | 0.255 |
| Change from baseline to month 6 | 8.1 ± 25.9 | −2.2 ± 16.4 | 0.138 |
| p value* | 0.167 | 0.555 | |
| Change from baseline to month 12 | −1.1 ± 25.8 | −1.9 ± 19.3 | 0.902 |
| p value* | 0.854 | 0.660 | |
Variables are expressed as the mean ± SD
OC osteocalcin, PINP amino-terminal propeptide of procollagen type 1, CTX carboxy-terminal telopeptide of type 1 collagen, U-NTX urinary amino-terminal telopeptide of type 1 collagen
* p value after therapy versus baseline